CopyPastehas never been so tasty!

Pharmaceutical Nanotechnology Congregation 2013

by prbharatbook

  • 0
  • 0
  • 0
43 views promote a new conference "Pharmaceutical Nanotechnology Congregation 2013" from which you can Learn from the experts on the technical, quality, and regulatory considerations of nanotechnology.
 Pharmaceutical Nanotechnology Congregation 2013 To be held on 15th-16th October 2013 at Hilton Hotel, London, UK
 Nanotechnology has supported breakthrough innovation across many industries especially Pharmaceutical. Nanotechnology brings revolutionary changes in the field of life sciences including drug delivery, diagnostics, nutraceuticals and production of biomaterials. Pharmaceutical industry is facing unique pressure in bringing out their products to the market quicker and with a higher probability of success. Nanotechnology presents a possibility for all pharmaceutical companies to improve upon existing safe therapies and enjoy patent protection or significant increase the bioavailability of new molecular entities in development. Understanding the technical and regulatory hurdles necessary to safely and effectively leverage nanotechnology is the first step to realizing the potential benefits of this approach. Moreover, many pharmaceutical companies have begun exploiting nanotechnology in improving drug delivery and targeting. In oncology, for instance, nanomedicines are being tested for their ability to reach cell targets that have otherwise eluded more conventional medicines.
 Nanomaterials have been increasingly recognized as a promising component of the future of biotechnology and biomedicine. The global market for nanomedicine was valued at $72.8 billion in 2011 and is projected to grow at a robust compound annual growth rate (CAGR) of 12.5%, reaching $130.9 billion by 2016. The overall anticancer nanomedicine market reached $28 billion in 2011, up from $16.4 billion in 2006, a 71% increase. It is expected to reach $46.7 billion by 2016, a CAGR of 10.8% between 2011 and 2016.
 Yet, the nature of this scientific advancement remains surrounded by “unknown unknowns.” And there is a need for companies—in the pharma sector and beyond—to be proactive in the management and communication of this technology. So for pharmaceutical companies, the question is not, “Is nano a stakeholder concern?” but rather, “What do we need to learn, and then what do we need to show our stakeholders to gain their trust?”
 Due to the variety of potential applications (including industrial and military), governments have invested billions of dollars in nanotechnology research. Through its National Nanotechnology Initiative, the USA has invested 3.7 billion dollars. The European Union has invested 1.2 billion and Japan 750 million dollars.
 Key Speakers:-
 Marianne Ashford, Drug Delivery – Principal Scientist, AstraZeneca
 Sumit Munjal, EU Medical Advisor & Pharmacovigilance Director, Global Safety - Oncology Portfolio, Takeda
 Tom Kurzawinski, Consultant Pancreatic and Endocrine Surgeon, University College London Hospitals - NHS Foundation Trust, Royal Free Hospital
 Sanyogitta Puri, Senior Scientist - Medicines Evaluation, Pharmaceutical Development, AstraZeneca
 Milos Todorovic, Lead Analyst - Practice Leader, Lux Research (Boston, USA)
 Helen Townley, Senior Research Fellow - Dept. Engineering Science, Oxford University
 Brij Patel, CEO, RegExcelconsulting (Former Biological Assessor, MHRA)
 Ijeoma F. Uchegbu, Chair in Pharmaceutical Nanoscience, Department of Pharmaceutics, UCL School of Pharmacy
 Twan Lammers, Head of work groups - Department of experimental molecular imaging, University of Twente (Germany)
 Jeffrey H. Rosedale, Partner, Woodcock Washburn (Philadelphia)
 Peter Bogaert, Managing Partner, Covington & Burling (Belgium)
 For more information kindly visit :                             
 Contact us at :
 Company Profiles And Conferences
 Phone: +919223375060 / 919223767111
 Fax: +91 22 27810778
 Email :
 Website :

Add A Comment: